383 related articles for article (PubMed ID: 33345396)
1. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
Xu J; Bai Y; Li E; Xu N; Shi D; Qian J
Expert Rev Anticancer Ther; 2022 Sep; 22(9):981-998. PubMed ID: 35950848
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis.
Xu JX; Maher VE; Zhang L; Tang S; Sridhara R; Ibrahim A; Kim G; Pazdur R
Oncologist; 2017 Mar; 22(3):311-317. PubMed ID: 28232599
[TBL] [Abstract][Full Text] [Related]
8. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L; Kato K; Kim SB; Ajani JA; Zhao K; He Z; Yu X; Shu Y; Luo Q; Wang J; Chen Z; Niu Z; Zhang L; Yi T; Sun JM; Chen J; Yu G; Lin CY; Hara H; Bi Q; Satoh T; Pazo-Cid R; Arkenau HT; Borg C; Lordick F; Li L; Ding N; Tao A; Shi J; Van Cutsem E;
J Clin Oncol; 2022 Sep; 40(26):3065-3076. PubMed ID: 35442766
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
14. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
[TBL] [Abstract][Full Text] [Related]
15. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G; Miyakoshi J; Yamamoto S; Kato K
Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma.
Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
Front Oncol; 2023; 13():1126536. PubMed ID: 37139161
[TBL] [Abstract][Full Text] [Related]
19. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3).
Takahashi M; Kato K; Okada M; Chin K; Kadowaki S; Hamamoto Y; Doki Y; Kubota Y; Kawakami H; Ogata T; Hara H; Muto M; Nakashima Y; Ishihara R; Tsuda M; Motoyama S; Kodani M; Kitagawa Y
Esophagus; 2021 Jan; 18(1):90-99. PubMed ID: 33170461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
